TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group

Lisa Wray, Marijana Vujkovic, Thomas Mcwilliams, Shannon Cannon, Meenakshi Devidas, Linda Stork, Richard Aplenc

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Sinusoidal obstruction syndrome is a complication of therapy for pediatric ALL and may be modified by thiopurine methyltransferase activity as well as by MTHFR genotype. We assessed TPMT *3A, *3B, *3C, and MTHFR C677T and A1298C germline genetic polymorphisms among 351 patients enrolled in the thioguanine treatment arm of CCG-1952 clinical trial. TPMT and MTHFR C677T genotypes were not associated with SOS risk. The combination of MTHFR and TPMT variant genotypes was not associated with SOS risk. These suggest that germline genetic variation in TPMT and MTHFR do not significantly alter SOS risk in patients exposed to thioguanine.

Original languageEnglish (US)
Pages (from-to)2086-2088
Number of pages3
JournalPediatric Blood and Cancer
Volume61
Issue number11
DOIs
StatePublished - Nov 1 2014

Keywords

  • Acute lymphoblastic leukemia
  • MTHFR
  • SOS
  • TPMT
  • Thioguanine
  • Toxicity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group'. Together they form a unique fingerprint.

  • Cite this